GURUFOCUS.COM » STOCK LIST » USA » NAS » Amgen Inc (NAS:AMGN) » Definitions » Debt-to-Equity
Switch to:

Amgen (NAS:AMGN) Debt-to-Equity

: 7.90 (As of Sep. 2023)
View and export this data going back to 1983. Start your Free Trial

Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1,428 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $59,040 Mil. Amgen's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $7,656 Mil. Amgen's debt to equity for the quarter that ended in Sep. 2023 was 7.90.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Amgen's Debt-to-Equity or its related term are showing as below:

AMGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 1.1   Med: 2.56   Max: 40.23
Current: 7.9

During the past 13 years, the highest Debt-to-Equity Ratio of Amgen was 40.23. The lowest was 1.10. And the median was 2.56.

AMGN's Debt-to-Equity is ranked worse than
98.48% of 855 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs AMGN: 7.90

Amgen Debt-to-Equity Historical Data

The historical data trend for Amgen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.71 3.09 3.51 4.97 10.64

Amgen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.60 10.64 11.52 9.08 7.90

Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Amgen's Debt-to-Equity falls into.



Amgen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Amgen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Amgen's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amgen  (NAS:AMGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Amgen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Amgen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (NAS:AMGN) Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Executives
Matthew C. Busch officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Michael V Drake director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Derek Miller officer: SVP, Human Resources ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Rachna Khosla officer: SVP, Business Development ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Amy E Miles director
Linda H. Louie officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Nancy A. Grygiel officer: SVP & CCO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Peter H. Griffith officer: EVP & CFO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Murdo Gordon officer: EVP Global Commercial Ops C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154
David M Reese officer: EVP, Research and Development ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Wanda M Austin director 6001 BOLLINGER CANYON ROAD, SAN RAMON CA 94583
Charles M Holley director
Lori A Johnston officer: SVP, HR C/O AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320